How the FDA Could Shape the Future of Psychedelics Research
(Originally published by www.undark.org, Aug 5, 2024) In August, the US Food and Drug Administration decided not to approve the psychedelic drug MDMA (midomafetamine) for use in patients with post-traumatic stress disorder in conjunction with psychological intervention. The move signals the FDA’s desire to put the brakes on the psychedelics research, which has rapidly moved […]